IRONWOOD PHARMACEUTICALS INC (IRWD)

Company Profile

Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 219 full-time employees. The company went IPO on 2010-02-03. The company develops and commercializes GI product opportunities in areas of unmet need, leveraging its expertise and capabilities in GI diseases. LINZESS (linaclotide), its commercial product, is a class of GI medicines called guanylate cyclase type C agonists (GC-C agonists) and is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC in Canada, and to adult men and women suffering from IBS-C in certain European countries. The firm is also advancing apraglutide, a synthetic peptide analog of glucagon-like peptide-2 (GLP-2), for rare GI diseases, including short bowel syndrome with intestinal failure (SBS-IF).

Company Info

IRONWOOD PHARMACEUTICALS INC

100 Summer Street, Suite 2300

Boston MASSACHUSETTS 02110

P: 16176217722

CEO: Mark Mallon

Employees: 219

Website: https://www.ironwoodpharma.com/